Acute Hepatic Porphyria Treatment Market Size & Share, By Drug Class (Givosiran, Hemin, Carbohydrate Loading); Distribution Channel - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

Acute Hepatic Porphyria Treatment Sector: Growth Drivers and Challenges

Growth Drivers

• Improved quality in medical care: One of the primary drivers in the acute hepatic porphyria treatment market is the improved quality in the healthcare sector, prioritizing higher efficacy in the long run. In this regard, in 2022, AHRQ reported that early management utilizing givosiran, which is an RNA interference therapy for AHP, tremendously reduced hospitalizations by 45%. This reduction resulted in cost savings of USD 220 million in a span of two years in the U.S. Besides, NIH states that healthcare facilities that introduced strict treatment protocols saw a significant reduction of ER room visits by 32%. Hence, these factors highlight the global adoption of improved quality with RNAi therapy, thereby driving growth in this sector.
   
• Unmet medical needs: Another significant driver in the acute hepatic porphyria treatment market is the unmet medical needs of patients, especially from developing regions. For instance, MHLW reported that there is a huge opportunity for AHP treatment in the country, as patients are lacking access to givosiran due to its high cost. These highlighted health disparities among the patients across developing nations are anticipated to boost the market expansion for AHP treatments.

Historical Patient Growth and Its Impact on AHP Market Expansion

The acute hepatic porphyria treatment market has witnessed remarkable growth opportunities over the last decade due to the rising diagnostic advancements, increasing awareness to mitigate long-term complications, and the evolving treatment procedures. Besides, there is a fast-rising prevalence of acute hepatic porphyria; in this regard, North America and Europe are leading the market owing to their advanced medical infrastructure and growing early detection capabilities. Furthermore, in the U.S., Germany, and Japan, the introduction of hemin therapies such as Panhematin/Normosang and later givosiran (Givlaari) significantly reduced acute attacks, improving patient outcomes, thereby supporting market development.

Historical Patient Growth (2010–2020) for AHP Treatment

(Sources: NIH GARD, EU Rare Disease Registries, MHLW, ICMR)

Manufacturer Strategies Strengthening Acute Hepatic Porphyria (AHP) Market Positions

Manufacturers involved in the acute hepatic porphyria treatment market are gaining traction with magnifying strategies to strengthen their ecosystems in the global market. Key trends opted by global leaders include exclusive product transformations, increased access, and strategic partnerships. For instance, in 2023, NIH declared that Alnylam Pharmaceuticals launched givosiran, which is an RNAi therapy, that lowered attack rates by 75% in clinical trials. Besides, in 2022, NORD took an initiative to conduct patient support programs to address the unmet medical needs for rare diseases. Furthermore, the focus on personalized medicine and supportive regulatory frameworks accelerates R&D in the field.

The table below highlights revenue potential from key AHP treatment strategies:

Challenge

• High costs of treatment:  One of the major restricting barriers for the acute hepatic porphyria treatment market is the high cost associated with the AHP treatments across the world. It is reported that Alnylam Pharmaceutical’s Givlaari (givosiran), which is one of the U.S. FDA-cleared therapies, costs around USD 575,000 annually for each patient. This can hinder the market penetration in price-sensitive regions, making it challenging for patients to afford them. Besides, this can create a major hurdle for healthcare facilities as the costs are unsustainable, negatively impacting market upliftment.